Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder
SAN DIEGO, Dec. 23, 2021 /PRNewswire/ — Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt of correspondence from the U.S….
Comments Off on Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder